OHSU spinout raised $1.5M for cancer drug platform
An Oregon Health& Science University spinout raised $1.5 million, which will help advance its cancer drug candidate toward a clinical trial.
PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni& Joan E. Kuni Foundation, based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities& Exchange Commission.
PDX Pharmaceuticals’ first drug candidate is targeted for treatment of HER2-positive breast cancer, which accounts for…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Funding | Health Management | HER2 | Science